BEVERLY, MA– February 11, 2019 – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with the U.S. Securities and Exchange Commission its Quarterly Report on Form 10-Q for the quarter ended December 31, 2018. The filing is available on the Company’s website under the “Financials & Filings” tab.
“We’re excited about 2019 and the opportunities surrounding our drug candidates. We see an industry where large pharmas are in need of replenishing their pipelines and, to that point, there has been plenty of interest in Brilacidin due to its unique qualities, broad applications and impressive body of clinical and pre-clinical data,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We are active in advanced discussions with a variety of pharmaceuticals companies. Our goal remains to secure a partner for advanced clinical development of Brilacidin as a new therapeutic for Oral Mucositis and Inflammatory Bowel Disease. At that time, we intend to focus our resources on the next stages of development for Brilacidin, notably dermatologic indications, and Kevetrin as a novel anti-cancer agent to build upon the completed studies.”
"They have term debt owed to insiders who presumably won't sue for payment until they have to."
Is that still an entirely reasonable assumption given that KM only meets the definition of insider by the 10% holding criteria and is no longer an Officer or Director? I believe that approximately $3M is due to him and his family's Company (Kard).
Do you think that his separation from IPIX was friendly enough to allow that debt to continue to slide without objection?
News 
Market Data 
Discover 
AI
